

Silvia Soddu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1689484/publications.pdf>

Version: 2024-02-01

121
papers

5,539
citations

57758

44
h-index

88630

70
g-index

126
all docs

126
docs citations

126
times ranked

6591
citing authors

#	ARTICLE	IF	CITATIONS
1	Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. <i>Nature Cell Biology</i> , 2002, 4, 11-19.	10.3	636
2	p53 Inhibits β 6 β 4 Integrin Survival Signaling by Promoting the Caspase 3-Dependent Cleavage of Akt/PKB. <i>Journal of Cell Biology</i> , 1999, 147, 1063-1072.	5.2	171
3	MDM2-Regulated Degradation of HIPK2 Prevents p53Ser46 Phosphorylation and DNA Damage-Induced Apoptosis. <i>Molecular Cell</i> , 2007, 25, 739-750.	9.7	161
4	NF-Y Mediates the Transcriptional Inhibition of the cyclin B1, cyclin B2, and cdc25C Promoters upon Induced G2 Arrest. <i>Journal of Biological Chemistry</i> , 2001, 276, 5570-5576.	3.4	153
5	p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. <i>Oncogene</i> , 1997, 14, 729-740.	5.9	141
6	TP53INP1s and Homeodomain-interacting Protein Kinase-2 (HIPK2) Are Partners in Regulating p53 Activity. <i>Journal of Biological Chemistry</i> , 2003, 278, 37722-37729.	3.4	140
7	Interference with p53 protein inhibits hematopoietic and muscle differentiation. <i>Journal of Cell Biology</i> , 1996, 134, 193-204.	5.2	118
8	HIPK2: a multitasking partner for transcription factors in DNA damage response and development This paper is one of a selection of papers published in this Special Issue, entitled 28th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process. <i>Biochemistry and Cell Biology</i> , 2007, 85, 411-418.	2.0	115
9	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. <i>Blood</i> , 1998, 91, 4342-4349.	1.4	112
10	Growth and Differentiation Signals by the Insulin-like Growth Factor 1 Receptor in Hemopoietic Cells Are Mediated through Different Pathways. <i>Journal of Biological Chemistry</i> , 1999, 274, 12423-12430.	3.4	108
11	Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 46.	8.6	108
12	p53 Regulates Myogenesis by Triggering the Differentiation Activity of Prb. <i>Journal of Cell Biology</i> , 2000, 151, 1295-1304.	5.2	107
13	p53 Displacement from Centrosomes and p53-mediated G1 Arrest following Transient Inhibition of the Mitotic Spindle. <i>Journal of Biological Chemistry</i> , 2001, 276, 19205-19213.	3.4	107
14	Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. <i>Cancer Cell</i> , 2006, 10, 473-486.	16.8	106
15	Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. <i>Experimental Cell Research</i> , 2004, 293, 311-320.	2.6	99
16	Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis. <i>Molecular and Cellular Biology</i> , 2006, 26, 4746-4757.	2.3	93
17	p53 Localization at Centrosomes during Mitosis and Postmitotic Checkpoint Are ATM-dependent and Require Serine 15 Phosphorylation. <i>Molecular Biology of the Cell</i> , 2004, 15, 3751-3757.	2.1	92
18	Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. <i>Journal of Molecular Medicine</i> , 2009, 87, 1221-1239.	3.9	88

#	ARTICLE	IF	CITATIONS
19	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. <i>Journal of Clinical Investigation</i> , 2007, 117, 693-702.	8.2	88
20	Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 63.	8.6	81
21	ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 95.	8.6	81
22	From p63 to p53 across p73. <i>FEBS Letters</i> , 2001, 490, 163-170.	2.8	79
23	Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb. <i>Cancer Cell</i> , 2002, 2, 387-399.	16.8	76
24	MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. <i>EMBO Journal</i> , 2009, 28, 1926-1939.	7.8	75
25	Activation of p53 Function in Carcinoma Cells by the β 4 Integrin. <i>Journal of Biological Chemistry</i> , 1999, 274, 20733-20737.	3.4	66
26	High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. <i>Cell Death and Differentiation</i> , 2006, 13, 1554-1563.	11.2	65
27	HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. <i>Oncogene</i> , 2005, 24, 5431-5442.	5.9	63
28	ATM is Activated by Default in Mitosis, Localizes at Centrosomes and Monitors Mitotic Spindle Integrity. <i>Cell Cycle</i> , 2006, 5, 88-92.	2.6	63
29	Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. <i>EMBO Reports</i> , 2009, 10, 1327-1333.	4.5	63
30	Mitotic cycle reactivation in terminally differentiated cells by adenovirus infection. <i>Journal of Cellular Physiology</i> , 1995, 162, 26-35.	4.1	61
31	HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. <i>Oncogene</i> , 2004, 23, 5185-5192.	5.9	60
32	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. <i>Oncogene</i> , 2015, 34, 2493-2504.	5.9	59
33	HIPKs: Jack of all trades in basic nuclear activities. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 2124-2129.	4.1	58
34	HIPK2 Controls Cytokinesis and Prevents Tetraploidization by Phosphorylating Histone H2B at the Midbody. <i>Molecular Cell</i> , 2012, 47, 87-98.	9.7	58
35	HIPK2 phosphorylates p63 and promotes its degradation in response to DNA damage. <i>Oncogene</i> , 2011, 30, 4802-4813.	5.9	57
36	c-Abl acetylation by histone acetyltransferases regulates its nuclear-cytoplasmic localization. <i>EMBO Reports</i> , 2006, 7, 727-733.	4.5	55

#	ARTICLE	IF	CITATIONS
37	The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas. <i>PLoS ONE</i> , 2011, 6, e20665.	2.5	54
38	Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization. <i>Cancer Research</i> , 2005, 65, 9687-9694.	0.9	53
39	Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status. <i>International Journal of Radiation Biology</i> , 2014, 90, 248-255.	1.8	53
40	Pax8 has a critical role in epithelial cell survival and proliferation. <i>Cell Death and Disease</i> , 2013, 4, e729-e729.	6.3	50
41	HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA. <i>Cancer Research</i> , 2009, 69, 6241-6248.	0.9	49
42	Negative Regulation of β 4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression. <i>Cancer Research</i> , 2009, 69, 5978-5986.	0.9	48
43	HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 1443-1453.	4.1	47
44	Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.. <i>Journal of Clinical Investigation</i> , 1996, 98, 1165-1173.	8.2	47
45	5 α -Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. <i>FASEB Journal</i> , 2004, 18, 1740-1742.	0.5	40
46	p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. <i>Cell Death and Differentiation</i> , 2004, 11, 596-607.	11.2	40
47	PKC Theta Ablation Improves Healing in a Mouse Model of Muscular Dystrophy. <i>PLoS ONE</i> , 2012, 7, e31515.	2.5	39
48	MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. <i>Cell Death and Disease</i> , 2018, 9, 895.	6.3	35
49	Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. <i>Oncogene</i> , 2000, 19, 3245-3255.	5.9	34
50	Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 108.	8.6	34
51	<i>Gal-3</i> is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. <i>Journal of Pathology</i> , 2009, 218, 66-75.	4.5	33
52	HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. <i>Cell Proliferation</i> , 2009, 42, 373-384.	5.3	33
53	Epithelial-to-mesenchymal transition and invasion are upmodulated by tumor-expressed granzyme B and inhibited by docosahexaenoic acid in human colorectal cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 24.	8.6	33
54	MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. <i>Oncogene</i> , 2016, 35, 228-240.	5.9	33

#	ARTICLE	IF	CITATIONS
55	Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. <i>Cell Death and Differentiation</i> , 2006, 13, 1994-1997.	11.2	32
56	Prognostic role of serum p53 antibodies in lung cancer. <i>BMC Cancer</i> , 2015, 15, 148.	2.6	32
57	Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. <i>Gene Therapy</i> , 1999, 6, 1064-1072.	4.5	31
58	p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. <i>Cell Death and Differentiation</i> , 2000, 7, 506-508.	11.2	31
59	HIPK2 Phosphorylates the Microtubule-Severing Enzyme Spastin at S268 for Abscission. <i>Cells</i> , 2019, 8, 684.	4.1	31
60	MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response. <i>Molecular Cancer Research</i> , 2011, 9, 67-77.	3.4	30
61	Mutant cohesin drives chromosomal instability in early colorectal adenomas. <i>Human Molecular Genetics</i> , 2014, 23, 6773-6778.	2.9	30
62	HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. <i>Oncotarget</i> , 2015, 6, 10320-10334.	1.8	30
63	Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. <i>British Journal of Cancer</i> , 1998, 77, 1429-1438.	6.4	29
64	Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. <i>Oncogene</i> , 2004, 23, 418-425.	5.9	29
65	The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells. <i>Oncogene</i> , 1999, 18, 5831-5835.	5.9	27
66	Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. <i>Journal of Gene Medicine</i> , 2000, 2, 11-21.	2.8	27
67	CDKL5 localizes at the centrosome and midbody and is required for faithful cell division. <i>Scientific Reports</i> , 2017, 7, 6228.	3.3	27
68	p53 mitotic centrosome localization preserves centrosome integrity and works as sensor for the mitotic surveillance pathway. <i>Cell Death and Disease</i> , 2019, 10, 850.	6.3	26
69	Mice with reduced expression of the telomere-associated protein Ft1 develop p53-sensitive progeroid traits. <i>Aging Cell</i> , 2018, 17, e12730.	6.7	24
70	HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53-dependent mitochondrial apoptosis. <i>EMBO Reports</i> , 2020, 21, e48073.	4.5	23
71	Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging. <i>Gene Therapy</i> , 1997, 4, 1371-1378.	4.5	21
72	Investigation into the reactivity of the coordinatively unsaturated phosphonodithioato [Ni(MeOpdt) ₂] towards 2,4,6-tris(2-pyridyl)-1,3,5-triazine: goals and achievements. <i>Dalton Transactions</i> , 2007, , 2127.	3.3	20

#	ARTICLE	IF	CITATIONS
73	Targeted Disruption of the Murine Homeodomain-Interacting Protein Kinase-2 Causes Growth Deficiency In Vivo and Cell Cycle Arrest In Vitro. <i>DNA and Cell Biology</i> , 2009, 28, 161-167.	1.9	20
74	p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes. <i>Journal of Clinical Investigation</i> , 2013, 123, 1335-1342.	8.2	20
75	Spastin recovery in hereditary spastic paraplegia by preventing neddylation-dependent degradation. <i>Life Science Alliance</i> , 2020, 3, e202000799.	2.8	19
76	Adenovirus Infection Induces Reentry into the Cell Cycle of Terminally Differentiated Skeletal Muscle Cells. <i>Annals of the New York Academy of Sciences</i> , 1995, 752, 9-18.	3.8	17
77	Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. <i>Cancer Letters</i> , 2006, 231, 102-112.	7.2	17
78	Retinoic acid and camp differentially regulate human chromogranin a promoter activity during differentiation of neuroblastoma cells. <i>European Journal of Cancer</i> , 1995, 31, 447-452.	2.8	16
79	A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug. <i>Investigational New Drugs</i> , 2005, 23, 195-203.	2.6	16
80	TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability. <i>Cancer Letters</i> , 2020, 473, 98-106.	7.2	16
81	Discrimination of single amino acid mutations of the p53 protein by means of deterministic singularities of recurrence quantification analysis. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 55, 743-755.	2.6	15
82	HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis. <i>Oncogene</i> , 2018, 37, 3562-3574.	5.9	15
83	The Cockayne syndrome group A and B proteins are part of a ubiquitinâ€“proteasome degradation complex regulating cell division. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 30498-30508.	7.1	15
84	hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. <i>Oncogene</i> , 2016, 35, 887-896.	5.9	13
85	An Alternative Splice Variant of HIPK2 with Intron Retention Contributes to Cytokinesis. <i>Cells</i> , 2020, 9, 484.	4.1	13
86	Evaluating virus-transformed cell tumorigenicity. <i>Journal of Virological Methods</i> , 1999, 79, 41-50.	2.1	12
87	Evaluation of the molecular mechanisms involved in the gain of function of a Li-FraumeniTP53 Mutation. <i>Human Mutation</i> , 2005, 26, 94-103.	2.5	12
88	p53 Detection by Fluorescence Lifetime on a Hybrid Fluorescein Isothiocyanate Gold Nanosensor. <i>Journal of Biomedical Nanotechnology</i> , 2009, 5, 683-691.	1.1	12
89	Wild-type p53 differentially affects tumorigenic and metastatic potential of murine metastatic cell variants. <i>Clinical and Experimental Metastasis</i> , 1993, 11, 368-376.	3.3	11
90	Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. <i>British Journal of Cancer</i> , 1998, 78, 1541-1546.	6.4	11

#	ARTICLE	IF	CITATIONS
91	HIPK2 sustains apoptotic response by phosphorylating Che-1/AATF and promoting its degradation. <i>Cell Death and Disease</i> , 2014, 5, e1414-e1414.	6.3	11
92	The β 4 Integrin Subunit Is Expressed in Mouse Fibroblasts and Modulated by Transforming Growth Factor- β 1. <i>Experimental Cell Research</i> , 1996, 227, 223-229.	2.6	10
93	Serum p53 antibody detection in patients with impaired lung function. <i>BMC Cancer</i> , 2013, 13, 62.	2.6	10
94	Cloning of the Mouse Insulin Receptor Substrate-3 (mIRS-3) Promoter, and Its Regulation by p53. <i>Molecular Endocrinology</i> , 2002, 16, 1577-1589.	3.7	9
95	Homeodomain-interacting Protein Kinase-2 Stabilizes p27kip1 by Its Phosphorylation at Serine 10 and Contributes to Cell Motility. <i>Journal of Biological Chemistry</i> , 2011, 286, 29005-29013.	3.4	9
96	Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 135.	8.6	9
97	Homeodomain Interacting Protein Kinase 2 Activation Compromises Endothelial Cell Response to Laminar Flow: Protective Role of p21waf1,cip1,sdi1. <i>PLoS ONE</i> , 2009, 4, e6603.	2.5	8
98	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. <i>Oncotarget</i> , 2017, 8, 108463-108479.	1.8	8
99	HIPK2 Is Required for Midbody Remnant Removal Through Autophagy-Mediated Degradation. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 572094.	3.7	7
100	Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties. <i>Cell Death and Disease</i> , 2021, 12, 558.	6.3	7
101	Development of a murine orthotopic model of leukemia: Evaluation of TP53 gene therapy efficacy. <i>Cancer Gene Therapy</i> , 2000, 7, 135-143.	4.6	6
102	HIPK2-T566 autophosphorylation diversely contributes to UV- and doxorubicin-induced HIPK2 activation. <i>Oncotarget</i> , 2017, 8, 16744-16754.	1.8	6
103	Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. <i>Oncogene</i> , 1997, 15, 607-611.	5.9	5
104	Apoptosis induced by a HIPK2 full-length-specific siRNA is due to off-target effects rather than prevalence of HIPK2- β 8 isoform. <i>Oncotarget</i> , 2016, 7, 1675-1686.	1.8	5
105	HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression. <i>Molecular Cancer Research</i> , 2022, 20, 686-698.	3.4	5
106	Effects of Y361 auto-phosphorylation on structural plasticity of the HIPK2 kinase domain. <i>Protein Science</i> , 2018, 27, 725-737.	7.6	4
107	Extrachromosomal Histone H2B Contributes to the Formation of the Abscission Site for Cell Division. <i>Cells</i> , 2019, 8, 1391.	4.1	4
108	The effects of end point overdispersions on the validity of single-dose tumorigenicity assays. <i>Cancer Letters</i> , 1995, 93, 179-186.	7.2	3

#	ARTICLE	IF	CITATIONS
109	Genomic instability associated with myotonic dystrophy does not involve p53 expression and activity. , 1998, 16, 117-122.		3
110	Immune response to cytomegalovirus in patients with acquired-immunodeficiency syndrome related complex (ARC) and AIDS. European Journal of Epidemiology, 1987, 3, 439-441.	5.7	2
111	In-vitro and in-vivo detection of p53 by fluorescence lifetime on a hybrid FITC-gold nanosensor. , 2010, , .		2
112	Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSE1 gene. Life Science Alliance, 2021, 4, e202101019.	2.8	2
113	Cloning of the Mouse Insulin Receptor Substrate-3 (mIRS-3) Promoter, and Its Regulation by p53. Molecular Endocrinology, 2002, 16, 1577-1589.	3.7	2
114	HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer. Oncology Reports, 2020, 45, 899-910.	2.6	2
115	Studies on Cell-mediated Immune Defects to Epstein-Barr Virus and Cytomegalovirus in HIV-related Disorders. Annals of the New York Academy of Sciences, 1987, 511, 385-389.	3.8	1
116	Abstract 4316: hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. , 2015, , .		1
117	Analysis of the Role of p53 and Galectin-3 in Proliferation and Apoptosis of Thyroid carcinoma cell lines by specific RNA interference experiments. Biomedicine and Pharmacotherapy, 2006, 60, 491.	5.6	0
118	467 HIPK2 in the Control of Chromosomal Instability – a New Mechanism in Tumorigenesis. European Journal of Cancer, 2012, 48, S112.	2.8	0
119	Functional Classification of the ATM Variant c.7157C>A and In Vitro Effects of Dexamethasone. Frontiers in Genetics, 2021, 12, 759467.	2.3	0
120	Abstract P3-06-01: ATM Heterozygosity as a Breast Cancer-Susceptibility Factor in the General Population. , 2010, , .		0
121	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. Journal of Clinical Investigation, 2013, 123, 4979-4979.	8.2	0